You need to login...
If you are not registered...
| Subscribe to Krixos Health: | |
|
or call us on: +43 (0)1 27 63 015 or email: subscribe@krixos.com |
|
Most viewed
- 1. ALKBH3-regulated m1A of ALDOA potentiates glycolysis and doxorubicin resistance of triple negative breast cancer cells
- 2. A bibliometric analysis of liver cancer bone metastases: advances in mechanisms of occurrence and treatment options
- 3. Angelini Ventures Co-leads CHF 79 Million (€84 Million) Series B Financing of NUCLIDIUM to Advance Clinical Development of its Copper-based Radiopharmaceutical Platform
- 4. BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in "Eye-Bulging" Breast Cancer Patient
- 5. Swiss BioTech platform NUCLIDIUM raises €84 million for the diagnosis and treatment of cancer
- 6. Radiopharma's new wave: Nuclidium and Actithera raise the stakes
- 7. ALKBH3-regulated m1A of ALDOA potentiates glycolysis and doxorubicin resistance of triple negative breast cancer cells
- 8. ESCO2 inhibition induces cell cycle arrest and apoptosis in breast cancer via the P53-CDK1 axis and the BAX/Bcl2/caspase signaling cascade
- 9. Baseline MRI habitat imaging for predicting treatment response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
- 10. Ultrasound-based radiomics combined with B3GALT4 level to predict sentinel lymph node metastasis in primary breast cancer
Last updated at 15:57 GMT
Hot News Makers
Health/Pharma Companies
-
24833.54
-
21911.95
-
14172.77
-
12448.34
-
9958.34
-
9419.11
-
5948.06
-
5430.04
-
3197.25
-
2747.21
Drugs, Treatments, Trials
-
53951.28
-
21405.20
-
9995.33
-
2559.02
-
1884.44
-
1689.91
-
1672.60
-
1408.26
-
1299.93
-
1263.12
Last updated at 15:10 GMT
